Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center.

ABSTRACT:

Background

Disparities in cancer outcomes persist between racial, ethnic, and socioeconomic groups. One potential cause is lack of appropriate representation in dose-finding clinical trials. We investigated the extent of disparities in phase I clinical trials and recent changes in the setting of institutional efforts to mitigate disparities, legislative interventions, FDA guidance for sponsors and the COVID-19 pandemic.

Methods

We performed a retrospective review of patients enrolled in phase I clinical trials at the University of Colorado Cancer Center in 2018-2019 and 2022-2023. We collected demographics, area deprivation index (ADI), tumor type and other clinical variables. Differences between cohorts were evaluated with t-tests, chi-Square test, or Fisher exact test. Pro

SUBMITTER: Alsafar A 

PROVIDER: S-EPMC12303809 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature